{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T19:28:04Z","timestamp":1786735684494,"version":"build-2736575974"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J Can Res Ther"],"published-print":{"date-parts":[[2020]]},"DOI":"10.4103\/jcrt.jcrt_465_17","type":"journal-article","created":{"date-parts":[[2018,10,26]],"date-time":"2018-10-26T08:32:53Z","timestamp":1540542773000},"page":"1","source":"Crossref","is-referenced-by-count":5,"title":["Combined modality treatment: Outcome in patients with Hodgkin's lymphoma"],"prefix":"10.4103","volume":"16","author":[{"given":"BudhiSingh","family":"Yadav","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"SureshC","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pankaj","family":"Malhotra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaurav","family":"Prakash","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"key-10.4103\/0973-1482.244217-1","first-page":"3065","volume-title":"An individual patient-data comparison of combined modality therapy and ABVD alone for patients with limited-stage Hodgkin lymphoma","author":"Hay","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.244217-2","first-page":"494","volume-title":"Combined modality treatment improves tumor control and overall survival in patients with early stage Hodgkin's lymphoma: A systematic review","author":"Herbst","year":"2010","journal-title":"Haematologica"},{"key":"key-10.4103\/0973-1482.244217-3","first-page":"3070","volume-title":"Impact of risk factors on outcomes in early-stage Hodgkin's lymphoma: An analysis of international staging definitions","author":"Klimm","year":"2013","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.244217-4","first-page":"640","volume-title":"Reduced treatment intensity in patients with early-stage Hodgkin's lymphoma","author":"Engert","year":"2010","journal-title":"N Engl J Med"},{"key":"key-10.4103\/0973-1482.244217-5","first-page":"4199","volume-title":"Intensified chemotherapy and dose-reduced involved-field radiotherapy in patients with early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin study group HD11 trial","author":"Eich","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-6","first-page":"907","volume-title":"Dose-intensification in early unfavorable Hodgkin's lymphoma: Final analysis of the German Hodgkin study group HD14 trial","author":"von","year":"2012","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-7","unstructured":"Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, et al . WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon, France: IARC Press; 2008."},{"key":"key-10.4103\/0973-1482.244217-8","first-page":"1860","volume-title":"Report of the committee on Hodgkin's disease staging classification","author":"Carbone","year":"1971","journal-title":"Cancer Res"},{"key":"key-10.4103\/0973-1482.244217-9","first-page":"1611","volume-title":"Treatment of favorable, limited-stage Hodgkin's lymphoma with chemotherapy without consolidation by radiation therapy","author":"Canellos","year":"2010","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-10","first-page":"2101","volume-title":"Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger","author":"Ng","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-11","first-page":"11;637a","volume-title":"Very long-term follow-up of the Danish National Hodgkin Study Group's randomized trial of radiotherapy (RT) alone vs.combined modality treatment (CMT) for early stage Hodgkin lymphoma, with special reference to second tumors and overall survival","author":"Specht","year":"2003","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244217-12","first-page":"1749","volume-title":"Second malignancy risk associated with treatment of Hodgkin's lymphoma: Meta-analysis of the randomised trials","author":"Franklin","year":"2006","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.244217-13","first-page":"3483","volume-title":"Results of a prospective randomized clinical trial of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) followed by radiation therapy (RT) versus ABVD alone for stages I, II, and IIIA nonbulky Hodgkin disease","author":"Straus","year":"2004","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244217-14","first-page":"6400","volume-title":"State-of-the-art therapeutics: Hodgkin's lymphoma","author":"Connors","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-15","first-page":"4574","volume-title":"Chemotherapy alone for early Hodgkin's lymphoma: An emerging option","author":"Canellos","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-16","first-page":"544","volume-title":"Don't throw out the baby with the bathwater: On optimizing cure and reducing toxicity in Hodgkin's lymphoma","author":"Yahalom","year":"2006","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-17","first-page":"3765","volume-title":"Randomized comparison of low-dose involved-field radiotherapy and no radiotherapy for children with Hodgkin's disease who achieve a complete response to chemotherapy","author":"Nachman","year":"2002","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-18","first-page":"835","volume-title":"Chemotherapy and combined modality therapy for Hodgkin's disease: A progress report on cancer and leukemia group B studies","author":"Bloomfield","year":"1982","journal-title":"Cancer Treat Rep"},{"key":"key-10.4103\/0973-1482.244217-19","first-page":"1466","volume-title":"Randomized trial of chemotherapy versus chemotherapy plus radiotherapy for stage I-II Hodgkin's disease","author":"Pavlovsky","year":"1988","journal-title":"J Natl Cancer Inst"},{"key":"key-10.4103\/0973-1482.244217-20","first-page":"95","volume-title":"A prospective clinical trial comparing chemotherapy, radiotherapy and combined therapy in the treatment of early stage Hodgkin's disease with bulky disease","author":"Aviles","year":"1998","journal-title":"Clin Lab Haematol"},{"key":"key-10.4103\/0973-1482.244217-21","first-page":"4634","volume-title":"Randomized comparison of ABVD chemotherapy with a strategy that includes radiation therapy in patients with limited-stage Hodgkin's lymphoma: National cancer institute of Canada Clinical Trials Group and the Eastern Cooperative Oncology Group","author":"Meyer","year":"2005","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-22","first-page":"814","volume-title":"Comparison of three radiation dose levels after EBVP regimen in favourable supradiaphragmatic clinical stages (CS) I\u2013II Hodgkin's lymphoma (HL): Preliminary results of the EORTC-GELA H9-F Trial","author":"Eghbali","year":"2005","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244217-23","first-page":"813","volume-title":"Four ABVD and involved field radiotherapy in unfavourable supradiaphragmatic clinical stages(CS) I II Hodgkin's lymphoma (HL): Preliminary results of the EORTC GELA H9 U trial","author":"Ferme","year":"2005","journal-title":"Blood"},{"key":"key-10.4103\/0973-1482.244217-24","first-page":"54","volume-title":"Low-dose consolidation radiation therapy for early stage unfavorable Hodgkin lymphoma","author":"Torok","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"key-10.4103\/0973-1482.244217-25","first-page":"2356","volume-title":"Radiation therapy for early stage unfavorable Hodgkin lymphoma: Is dose reduction feasible?","author":"Laskar","year":"2014","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0973-1482.244217-26","first-page":"3495","volume-title":"Two cycles of doxorubicin, bleomycin, vinblastine, and dacarbazine plus extended-field radiotherapy is superior to radiotherapy alone in early favorable Hodgkin's lymphoma: Final results of the GHSG HD7 trial","author":"Engert","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-27","first-page":"910","volume-title":"End-of-treatment but not interim PET scan predicts outcome in nonbulky limited-stage Hodgkin's lymphoma","author":"Barnes","year":"2011","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.244217-28","first-page":"1296","volume-title":"Early positron emission tomography (PET) restaging: A predictive final response in Hodgkin's disease patients","author":"Zinzani","year":"2006","journal-title":"Ann Oncol"},{"key":"key-10.4103\/0973-1482.244217-29","first-page":"3746","volume-title":"Early interim 2-[18F] fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin's lymphoma: A report from a joint Italian-Danish study","author":"Gallamini","year":"2007","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-30","first-page":"1188","volume-title":"Omitting radiotherapy in early positron emission tomography-negative stage I\/II Hodgkin lymphoma is associated with an increased risk of early relapse: Clinical results of the preplanned interim analysis of the randomized EORTC\/LYSA\/FIL H10 trial","author":"Raemaekers","year":"2014","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-31","first-page":"1721","volume-title":"Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans","author":"Picardi","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"key-10.4103\/0973-1482.244217-32","first-page":"270","volume-title":"Involved-node radiotherapy (INRT) in patients with early Hodgkin lymphoma: Concepts and guidelines","author":"Girinsky","year":"2006","journal-title":"Radiother Oncol"},{"key":"key-10.4103\/0973-1482.244217-33","first-page":"406","volume-title":"Involved-node radiotherapy in early-stage Hodgkin's lymphoma.Definition and guidelines of the German Hodgkin Study Group (GHSG)","author":"Eich","year":"2008","journal-title":"Strahlenther Onkol"},{"key":"key-10.4103\/0973-1482.244217-34","first-page":"4239","volume-title":"Breast cancer risk in female survivors of Hodgkin's lymphoma: Lower risk after smaller radiation volumes","author":"De","year":"2009","journal-title":"J Clin Oncol"},{"key":"key-10.4103\/0973-1482.244217-35","first-page":"854","volume-title":"Modern radiation therapy for Hodgkin lymphoma: Field and dose guidelines from the International Lymphoma Radiation Oncology Group (ILROG)","author":"Specht","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"}],"container-title":["Journal of Cancer Research and Therapeutics"],"original-title":[],"language":"en","deposited":{"date-parts":[[2026,8,14]],"date-time":"2026-08-14T18:32:23Z","timestamp":1786732343000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/10.4103\/jcrt.JCRT_465_17"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"references-count":35,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020]]}},"alternative-id":["244217"],"URL":"https:\/\/doi.org\/10.4103\/jcrt.jcrt_465_17","relation":{},"ISSN":["0973-1482"],"issn-type":[{"value":"0973-1482","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}